livermectine

Livermectine is not a widely recognized name for a pharmaceutical substance in major medical references. The term may be a misspelling or regional variant of ivermectin, a well-established antiparasitic medication. No official regulatory product or active ingredient by the exact name “livermectine” is listed in standard pharmacopoeias or drug databases.

Ivermectin is a macrocyclic lactone in the avermectin family. It works by binding to glutamate-gated chloride channels and other ligand-gated chloride channels in invertebrate nerve and muscle cells, causing paralysis and death of the parasite. It is used in humans to treat infections such as strongyloidiasis, onchocerciasis (river blindness), and scabies, and it is widely employed in veterinary medicine to control a range of nematode and ectoparasite infections in livestock, horses, and dogs.

Administration is typically oral for human use, with topical formulations available for dermatologic conditions. In animals, dosing varies by species and weight and is commonly administered under veterinary supervision. Ivermectin is generally well tolerated in humans, with common side effects including dizziness, pruritus, nausea, and mild fever. More serious adverse effects can occur in the setting of heavy parasite burdens or certain infections, such as loiasis or strongyloidiasis, due to rapid parasite die-off or high parasite loads.

Regulatory status: Ivermectin is listed by the World Health Organization as an essential medicine and is approved in many countries for its indicated human and veterinary uses. It has been the subject of misinformation regarding COVID-19; credible medical guidance does not support its use for treating or preventing COVID-19 outside approved indications. If “livermectine” refers to a specific regional product or a different compound, consult local regulatory databases or product labeling for accurate information.